Regardless of CXCR4 mutational status or mutation type (nonsense v frameshift), VGPR + complete response (CR) rates were numerically higher for zanubrutinib versus ibrutinib.7 In patients with baseline extramedullary disease, the VGPR + CR rate difference was 18.8% (95% CI, 2.4 to 35.1) favoring zanubrutinib, consistent with the greater median reduction observed in lymphadenopathy (65.9% v 52.5%) and splenomegaly (20.0% v 15.0%) for zanubrutinib versus ibrutinib, respectively. This evidence concerns the gene CXCR4 and Lymphadenopathy.